Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
May 2021
Historique:
received: 09 12 2020
revised: 18 02 2021
accepted: 26 02 2021
pubmed: 17 3 2021
medline: 8 2 2022
entrez: 16 3 2021
Statut: ppublish

Résumé

Symptomatic polycystic liver disease (PLD) with massive hepatomegaly represents a challenging surgical issue. In this work, we focused on early and long term outcomes after partial hepatectomy with cyst fenestration (PHCF) in selected patients. All patients who had PHCF for treatment of PLD between January 2003 and December 2019 in our center were included in this study. PHCF was undertaken if at least one hepatic section was relatively spared from PLD, afferent and efferent hepatic vasculature was patent, and liver function was maintained. Twenty nine patients (25 women) with a mean age of 54.6 ± 9 years underwent PHCF. Major hepatectomy was performed in all cases with 4.3 ± 0.8 resected segments. Overall perioperative morbidity (Clavien ≥ II) and mortality rates were 41.4.6% and 13.8% respectively. Significant postoperative liver volume reduction was 52.8% within the first year and 55.5% thereafter. From preoperative evaluation, performance status (PS) normalized or improved in 84% of patients. After a mean follow-up time of 70.8 ± 65 months, overall patient survival was 82.7%. In univariate analysis, PS, initial liver volume, operative time and transfusion were associated with post-operative complications and PS, preoperative cyst infection, portal hypertension, transfusion, postoperative sepsis and persistent ascites were associated with mortality. Our study confirms that in spite of significant morbidity rate, PHCF allows a massive reduction of liver volume in selected patients with symptomatic PLD and is highly and durably effective for the reduction of liver volume and improvement of quality of life.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Symptomatic polycystic liver disease (PLD) with massive hepatomegaly represents a challenging surgical issue. In this work, we focused on early and long term outcomes after partial hepatectomy with cyst fenestration (PHCF) in selected patients.
METHODS METHODS
All patients who had PHCF for treatment of PLD between January 2003 and December 2019 in our center were included in this study. PHCF was undertaken if at least one hepatic section was relatively spared from PLD, afferent and efferent hepatic vasculature was patent, and liver function was maintained.
RESULTS RESULTS
Twenty nine patients (25 women) with a mean age of 54.6 ± 9 years underwent PHCF. Major hepatectomy was performed in all cases with 4.3 ± 0.8 resected segments. Overall perioperative morbidity (Clavien ≥ II) and mortality rates were 41.4.6% and 13.8% respectively. Significant postoperative liver volume reduction was 52.8% within the first year and 55.5% thereafter. From preoperative evaluation, performance status (PS) normalized or improved in 84% of patients. After a mean follow-up time of 70.8 ± 65 months, overall patient survival was 82.7%. In univariate analysis, PS, initial liver volume, operative time and transfusion were associated with post-operative complications and PS, preoperative cyst infection, portal hypertension, transfusion, postoperative sepsis and persistent ascites were associated with mortality.
CONCLUSIONS CONCLUSIONS
Our study confirms that in spite of significant morbidity rate, PHCF allows a massive reduction of liver volume in selected patients with symptomatic PLD and is highly and durably effective for the reduction of liver volume and improvement of quality of life.

Identifiants

pubmed: 33722781
pii: S2210-7401(21)00049-8
doi: 10.1016/j.clinre.2021.101670
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101670

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Olivier Boillot (O)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France; Université Claude Bernard Lyon 1, France. Electronic address: olivier.boillot@chu-lyon.fr.

Bénédicte Cayot (B)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France.

Olivier Guillaud (O)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France; Ramsay Générale de Santé, Clinique de la Sauvegarde, Lyon, France.

Jessica Crozet-Chaussin (J)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France.

Valérie Hervieu (V)

Service d'anatomopathologie, Hôpital Femme Mère Enfant, Bron, France.

Pierre-Jean Valette (PJ)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France; Université Claude Bernard Lyon 1, France.

Jérôme Dumortier (J)

Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Pavillon D, 69437 Lyon Cedex 03, France; Université Claude Bernard Lyon 1, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH